Welcome
Support Centre
11 February 2012 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ Print-friendly version ]
A study to establish the efficacy of dexamethasone used in combination with cyclizine in the prevention of post operative nausea and vomiting
ISRCTN ISRCTN18556628
ClinicalTrials.gov identifier
Public title A study to establish the efficacy of dexamethasone used in combination with cyclizine in the prevention of post operative nausea and vomiting
Scientific title
Acronym N/A
Serial number at source N0355092655
Study hypothesis To investigate whether cyclizine is more effective than placebo in preventing post operative nausea and vomiting. A secondary aim is to establish whether a combination of cyclizine and dexamethasone is more effective than cyclizine alone.
Lay summary
Ethics approval Not provided at time of registration
Study design Randomised controlled trial
Countries of recruitment United Kingdom
Disease/condition/study domain Signs and Symptoms: Nausea and vomiting
Participants - inclusion criteria Women over the age of 18 undergoing daycase gynaecological laparoscopy.
Participants - exclusion criteria 1. Failure to consent
2. Under 18 years old
Anticipated start date 12/02/2001
Anticipated end date 03/12/2003
Status of trial Completed
Patient information material
Target number of participants 150
Interventions 1. Cyclizine 50mgs per-operatively and rescue ondansatron (control)
2. Dexamethasone 8mgs and cyclizine 50 mgs per-operatively and rescue ondansatron prn (combination)
3. 0.9% saline (placebo).

Randomisation: closed envelope technique. Anaesthetic: Propofol induction, nitrous oxide, isoflurane maintenance, Fentanyl 2 mgs/kg, Diclofenac 75 mgs I.v unless contraindicated. Patient airway maintained as deemed appropriate by the anaesthetist (recorded). Patient paralysed. All patients to receive iv fluids prn per-operatively. Paracetamol and/or codeine for rescue analgesia .
Primary outcome measure(s) Data and demographics recorded - age, time from LMP, smoking Hx, time from starvation, type of surgery, previous postoperative nausea and vomiting (PONV) , previous travel sickness, duration of anaesthesia, reversal used (Y/N), time to first oral intake, time to first mobilisation, time to first food, time to discharge. Vomiting (Y/N) or retching (Y/N) in recovery @ 1, 2, 3 & 4 hours, nausea (none/mild/moderate/severe) in recovery and @ 1, 2, 3 & 4 hour, pain score (non/mild/moderate/severe) in recovery and @ 1, 2, 3 & 4 hours, rescue anti emetic usage (ondansatron).
Secondary outcome measure(s) Not provided at time of registration
Sources of funding Mid Essex Hospital Services NHS Trust (UK)
NHS R&D Support Funding
Trial website
Publications 2004 abstract presented at Anaesthetic Research Society in Liverpool, British Journal of Anaesthesia 93 (4): 618P (2004): http://bja.oxfordjournals.org/cgi/content/citation/93/4/604P

Contact name Dr  Mark  Alexander-Williams
  Address Mid Essex Hospital Services NHS Trust (BH)
Broomfield Hospital
  City/town Chelmsford
  Zip/Postcode CM1 7ET
  Country United Kingdom
  Tel +44 (0)1245 516034
  Fax +44
  Email mark.alexander-williams@meht.nhs.uk
Sponsor Record Provided by the NHSTCT Register - 2005 Update - Department of Health (UK)
  Address The Department of Health
Richmond House
79 Whitehall
  City/town London
  Zip/Postcode SW1A 2NL
  Country United Kingdom
  Tel +44 (0)20 7307 2622
  Fax +44 (0)20 7307 2623
  Email dhmail@doh.gsi.org.uk
  Sponsor website: http://www.dh.gov.uk/Home/fs/en
Date applied 30/09/2005
Last edited 10/07/2008
Date ISRCTN assigned 30/09/2005
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2012 ISRCTN unless otherwise stated.


BioMed Central